266 related articles for article (PubMed ID: 32133274)
1. Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
Santos PB; Patel H; Henrique R; Félix A
World J Clin Oncol; 2020 Feb; 11(2):43-52. PubMed ID: 32133274
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.
Singh VK; Kainat KM; Sharma PK
Vitam Horm; 2023; 122():253-282. PubMed ID: 36863797
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
5. Epigenomics in stress tolerance of plants under the climate change.
Kumar M; Rani K
Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
[TBL] [Abstract][Full Text] [Related]
6. The genetics of neuroendocrine prostate cancers: a review of current and emerging candidates.
Ather MH; Siddiqui T
Appl Clin Genet; 2012; 5():105-10. PubMed ID: 23776386
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation and prostate cancer.
Majumdar S; Buckles E; Estrada J; Koochekpour S
Curr Genomics; 2011 Nov; 12(7):486-505. PubMed ID: 22547956
[TBL] [Abstract][Full Text] [Related]
9. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Modifications and Modulators in Prostate Cancer.
Cimadamore A; Gasparrini S; Scarpelli M; Doria A; Mazzucchelli R; Massari F; Cheng L; Lopez-Beltran A; Montironi R
Crit Rev Oncog; 2017; 22(5-6):439-450. PubMed ID: 29604923
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic (De)regulation in Prostate Cancer.
Xu C; Zhao S; Cai L
Cancer Treat Res; 2023; 190():321-360. PubMed ID: 38113006
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modifications in prostate cancer.
Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
[TBL] [Abstract][Full Text] [Related]
13. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.
Cucchiara V; Yang JC; Mirone V; Gao AC; Rosenfeld MG; Evans CP
Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28275218
[TBL] [Abstract][Full Text] [Related]
14. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.
Toiyama Y; Okugawa Y; Goel A
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):43-57. PubMed ID: 25128828
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.
Devaney JM; Wang S; Funda S; Long J; Taghipour DJ; Tbaishat R; Furbert-Harris P; Ittmann M; Kwabi-Addo B
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):292-300. PubMed ID: 23896626
[TBL] [Abstract][Full Text] [Related]
17. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
20. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Blute ML; Damaschke NA; Jarrard DF
Curr Opin Urol; 2015 Jan; 25(1):83-8. PubMed ID: 25405932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
